Skip to main content

Table 4 Outcomes in relation to specific adverse events in the Tamoxifen Exemestane Adjuvant Multinational (TEAM) trial[82]

From: Status of adjuvant endocrine therapy for breast cancer

Outcome measure AE Number of AEs (yes versus no AE) Hazard ratio 95% CI P value
DFS VMS 249 versus 837 0.731 0.618-0.866 <0.001
  MSAE 239 versus 847 0.826 0.694-0.982 0.030
  VVS 89 versus 997 0.769 0.585-1.01 0.058
  Overall 418 versus 668 0.735 0.632-0.855 <0.001
OS VMS 147 versus 617 0.583 0.424-0.803 0.001
  MSAE 151 versus 613 0.811 0.654-1.005 0.055
  VVS 51 versus 713 0.570 0.391-0.831 0.003
  Overall 268 versus 496 0.680 0.565-0.819 <0.001
DM VMS 165 versus 490 0.813 0.664-0.996 0.046
  MSAE 138 versus 517 0.749 0.601-0.934 0.010
  VVS 54 versus 601 0.687 0.435-1.085 0.107
  Overall 261 versus 394 0.783 0.651-0.942 0.010
  1. AE, adverse event; CI, confidence interval; DFS, disease-free survival; DM, distant metastases; MSAE, musculoskeletal adverse event; OS, overall survival; VMS, vasomotor symptoms; VVS, vulvovaginal symptoms.